US 12,138,235 B2
Cape-loaded targeted microvesicular cancer drug and method for developing the same
Fikrettin Sahin, Istanbul (TR); Pakize Neslihan Tasli, Istanbul (TR); Oguz Kaan Kirbas, Istanbul (TR); Ezgi Avsar Apdik, Istanbul (TR); and Huseyin Apdik, Istanbul (TR)
Assigned to Yeditepe Üniversitesi, Istanbul (TR)
Filed by YEDITEPE UNIVERSITESI, Istanbul (TR)
Filed on Jun. 15, 2022, as Appl. No. 17/840,700.
Application 17/840,700 is a division of application No. 16/955,087, granted, now 11,510,891, previously published as PCT/TR2018/050816, filed on Dec. 17, 2018.
Claims priority of application No. 2017/20642 (TR), filed on Dec. 18, 2017.
Prior Publication US 2022/0362194 A1, Nov. 17, 2022
Int. Cl. A61K 31/216 (2006.01); A61K 9/127 (2006.01)
CPC A61K 31/216 (2013.01) [A61K 9/1277 (2013.01)] 11 Claims
OG exemplary drawing
 
1. A method of producing a composition comprising caffeic acid phenethyl ester (CAPE) loaded microvesicles for targeting inhibition of SH-SY5Y neuroblastoma cancer growth, the method comprising the steps of:
A) seeding a plurality of skin stem cells in a culture medium,
B) implementing a specialization protocol to obtain a plurality of specialized skin cells, wherein the specialization protocol enables the plurality of skin stem cells in the culture medium reaching a confluency of 70-80% to be seeded in a plurality of 6-well cell culture plates whereby a feature of neuroblastoma recognition is provided to the plurality of skin stem cells enabling the plurality of skin stem cells to become targeted,
C) preparing a CAPE stock solution by dissolving the CAPE in dimethyl sulfoxide (DMSO),
D) performing a microvesicle isolation from the plurality of specialized skin cells to obtain a plurality of microvesicles,
E) adding the CAPE into the plurality of microvesicles,
F) separating a plurality of CAPE loaded microvesicles from the CAPE that is free in the CAPE stock solution and not loaded to the plurality of microvesicles,
G) obtaining the CAPE loaded microvesicles as a final product.